News
- Author:
- Andrew D. Bowser
Publish date: January 29, 2018
The phase 2 trial was closed early due to the difference in event-free survival favoring the neoadjuvant approach.
News
- Author:
- Andrew D. Bowser
Publish date: January 25, 2018
Dr. Cynthia Dunbar, of the NIH, talks about the “critical mass of successes” in hematology and what is coming in the future.
News
- Author:
- Andrew D. Bowser
Publish date: January 18, 2018
Analyses of early trials of atezolizumab for NSCLC and bladder cancer reveal aspects of immune-modified RECIST that seem to predict OS better than ...
News
- Author:
- Andrew D. Bowser
Publish date: January 17, 2018
Diagnosis appears to be the time with greatest risk.
News
- Author:
- Andrew D. Bowser
Publish date: January 16, 2018
BRCA-positive and BRCA-negative women had similar overall survival at 2 years, 5 years, and 10 years after diagnosis.
News
- Author:
- Andrew D. Bowser
Publish date: January 11, 2018
Frontline treatment with the oral fluoropyrimidine S-1 combined with irinotecan and bevacizumab was noninferior to other common regimens.
News
- Author:
- Andrew D. Bowser
Publish date: January 8, 2018
Real-world effectiveness study in Sweden found rituximab had lowest discontinuation rate of all disease-modifying treatments studied.
News
- Author:
- Andrew D. Bowser
Publish date: January 2, 2018
ATLANTA – Response rates ranged from 31% to 88% depending on the lymphoma subtype.
News
- Author:
- Andrew D. Bowser
Publish date: December 19, 2017
For patients with R0 pN2 NSCLC, median overall survival was 58.8 months for sequential chemotherapy followed by radiation, versus 40.4 months for c...
News
- Author:
- Andrew D. Bowser
Publish date: December 18, 2017
A 67-year-old man with Waldenstrom disease experienced bilateral facial nerve palsy.
News
- Author:
- Andrew D. Bowser
Publish date: December 18, 2017
Rituximab monotherapy appears to outperform splenectomy based on retrospective data.
Video
- Author:
- Andrew D. Bowser
Publish date: December 13, 2017
ATLANTA – Dr. Simon Rule discusses the implications of the study and how ibrutinib stacks up against other therapies for MCL.
News
- Author:
- Andrew D. Bowser
Publish date: December 12, 2017
ATLANTA – Lenalidomide as single agent had twice the VTE rate as lenalidomide with a biologic.
News
- Author:
- Andrew D. Bowser
Publish date: December 11, 2017
ATLANTA – A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy.
News
- Author:
- Andrew D. Bowser
Publish date: December 11, 2017
ATLANTA – The potential of two- and three-drug combinations to induce MRD-negative responses in CLL patients was demonstrated in multiple studies p...
